CLASS ACTION NOTICE: Berger Montague Advises Mereo BioPharma Group plc (MREO) Investors to Inquire About a Securities Fraud Class Action

February 11, 2026 8:41 AM EST | Source: Berger Montague

Philadelphia, Pennsylvania--(Newsfile Corp. - February 11, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company") on behalf of investors who purchased the American Depositary Shares ("ADS") of Mereo during the period from June 5, 2023 through December 26, 2025 (the "Class Period").

Investor Deadline: Investors who purchased Mereo securities during the Class Period may, no later than April 6, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

Mereo is a UK-based biopharmaceutical company engaged in the development of therapies for rare and serious conditions.

The complaint alleges that defendants misrepresented the results of the ORBIT and COSMIC Phase 3 programs testing the efficacy of setrusumab as a treatment of Osteogenesis Imperfecta.

According to the lawsuit, investors learned the truth on December 29, 2025, when Mereo disclosed that neither study had met its primary endpoint. This alleged reversal caused the Company's ADSs to lose more than 87% of their value in a single trading day.

If you are a Mereo investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.

About Berger Montague
Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.

For more information or to discuss your rights, please contact:
Andrew Abramowitz
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com

Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283222

info

Source: Berger Montague

Ready to Announce with Confidence?

Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us